Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 19Neoplasm Metastasis 6Brain Neoplasms 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Rare Tumour 1Prostatic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neuroma, Acoustic 1Neurofibromatosis 2 1Meningioma 1Malignant Female Reproductive System Neoplasm 1Hemangiosarcoma 1HER2-positive Breast Cancer 1HER2 Positive Breast Carcinoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Ependymoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Lobular 1Carcinoma 1

Interventions

Temozolomide 154Bevacizumab 88Radiotherapy 75Radiation 23Magnetic Resonance Spectroscopy 23Lomustine 18Irinotecan 18pembrolizumab 17Surgical Procedures, Operative 16Carmustine 16Erlotinib Hydrochloride 12Nivolumab 11Specimen Handling 10Aminolevulinic Acid 10sargramostim 9Thalidomide 9Chemotherapy, Adjuvant 9Carboplatin 9Drug Therapy 8Immunoglobulin G 7Filgrastim 7Etoposide 7Disulfides 7Cilengitide 7Sunitinib 6Sorafenib 6O(6)-benzylguanine 6Cyclophosphamide 6antineoplaston AS 2-1 5antineoplaston A10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Glioblastoma × neratinib × Clear all
NCT02977780 2025-11-10

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Dana-Farber Cancer Institute

Phase 2 Recruiting
460 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡